This study aims to characterize the epidemiology, clinicopathologic features, and survival outcomes of Chinese patients with PTCL; to develop and validate prognostic models to this population; to compare the real-world effectiveness and safety of alternative therapeutic strategies; to elucidate molecular mechanisms underlying treatment resistance and relapse; to identify actionable targets and predictive biomarkers.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥18 years, with a histopathologic diagnosis of PTCL (any subtype per WHO 2016 classification of hematolymphoid neoplasms).
* Cohort A: Patients diagnosed and treated at participating centers between 2010 and 2024.
* Cohort B: Patients newly diagnosed from October 2025 onward.
* Availability of basic diagnostic and treatment records .
Exclusion Criteria:
* Indeterminate diagnosis or missing pathology report.
* Patients diagnosed at an outside institution who did not receive their primary treatment and follow-up at a participating center.
* Diagnoses of NK/T-cell lymphoma or primary cutaneous T-cell lymphomas.
Primary outcome measure(s)
Distribution of PTCL Histological Subtypes according to WHO 2016 Classification — Baseline (at the time of enrollment or diagnosis) The number and percentage of participants diagnosed with each specific subtype of Peripheral T-Cell Lymphoma (e.g., PTCL-NOS, AITL, ALCL, ENKTL, etc.). Diagnosis is confirmed by pathological review based on the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition, 2017).
Overall Survival (OS) — 5 year after diagnosis OS is defined as the time from the date of pathological diagnosis to the date of death from any cause. For patients who are lost to follow-up, survival time will be censored at the date of last contact.
Progression-Free Survival (PFS) — 5 year after diagnosis PFS is defined as the time from the date of pathological diagnosis to the date of the first documented disease progression (PD) or death from any cause, whichever occurs first. Disease progression is assessed based on the investigator's evaluation of radiological and clinical data.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.